Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study (Q30381): Difference between revisions
Jump to navigation
Jump to search
Superraptor (talk | contribs) (Changed claim: author (P72): Jonathan Porter (Q30362)) |
Superraptor (talk | contribs) (Changed claim: author (P72): Jose Bauermeister (Q30373)) |
||
| (12 intermediate revisions by the same user not shown) | |||
| Property / author: Javier Lopez-Ríos / qualifier | |||
| Property / author: Elena Abascal / qualifier | |||
| Property / author: Elena Abascal / qualifier | |||
| Property / author: Curtis Dolezal / qualifier | |||
| Property / author: Michael P. Vaughn / qualifier | |||
| Property / author: Pilar Giffenig / qualifier | |||
| Property / author: Pilar Giffenig / qualifier | |||
| Property / author: Jasmine M. Lopez / qualifier | |||
| Property / author: Samantha Stonbraker / qualifier | |||
| Property / author: Christina Sun / qualifier | |||
| Property / author: Roque Anthony Velasco / qualifier | |||
| Property / author: Leandra Bitterfeld / qualifier | |||
| Property / author: Walter Bockting / qualifier | |||
| Property / author: Walter Bockting / qualifier | |||
| Property / author: Jose Bauermeister / qualifier | |||
| Property / author: Jose Bauermeister / qualifier | |||
Latest revision as of 02:40, 10 November 2024
No description defined
- Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study.
- Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study |
No description defined |
|
Statements
Long-acting injectable cabotegravir (CAB-LA) was US Food and Drug Administration-approved in 2021. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
However, little is known about providers' CAB-LA knowledge, attitudes, challenges, and prescribing preferences for transgender women patients. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Understanding this is critical to developing new pre-exposure prophylaxis (PrEP) interventions tailored to transgender women. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
We conducted 45-min, in-depth Zoom interviews (IDIs) with United States-based health care providers who prescribe PrEP to transgender women. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
IDIs focused on providers' CAB-LA knowledge/acceptability, willingness to prescribe CAB-LA to transgender women, potential challenges, and solutions to mitigate challenges. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Providers ( N = 17) had a mean age of 43 years, and 35.4% ( n = 6) identified as people of color. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Most ( n = 12) had basic knowledge of CAB-LA but wanted additional training. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
All participants found CAB-LA acceptable and were willing to prescribe. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Most ( n = 11) anticipated minimal challenges to implementation. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Others ( n = 4) reported potential issues, including logistical/scheduling concerns that impede CAB-LA integration and staffing concerns. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Many providers expressed support for self-injection ( n = 13) and injections at "drop-in" clinics ( n = 8) to overcome challenges. (English)
Copyright © 2024 Association of Nurses in AIDS Care. (English)
2024
Christine Tagliaferri (English)
Rael (English)
CT
Doyel (English)
Das (English)
D
Jonathan (English)
Porter (English)
J
Javier (English)
Lopez-Ríos (English)
J
Elena (English)
Abascal (English)
E
Curtis (English)
Dolezal (English)
C
Michael P (English)
Vaughn (English)
MP
Pilar (English)
Giffenig (English)
P
Jasmine M (English)
Lopez (English)
JM
Samantha (English)
Stonbraker (English)
S
Christina (English)
Sun (English)
C
Roque Anthony (English)
Velasco (English)
RA
Leandra (English)
Bitterfeld (English)
L
Walter O (English)
Bockting (English)
WO
Jose (English)
Bauermeister (English)
J
31 August 2024
28 August 2024
The authors report no real or perceived vested interests related to this article that could be construed as a conflict of interest. (English)
An early version of this manuscript was presented at the 2023 Western Institute of Nursing conference in Tuscon, Arizona, USA. (English)